# Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction

Study · id `cardio:ct-nct07146360` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07146360](<https://clinicaltrials.gov/study/NCT07146360>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07146360

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT07146360. Randomized; single masking; primary purpose treatment. Start 2014-05-25 (actual); primary completion 2017-11-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT07146360, source copy `cardio:ctgov-nct07146360-2025-08-28`, retrieved 2026-10-26)
- Started: 2014-05-25 (actual) (ClinicalTrials.gov record NCT07146360, source copy `cardio:ctgov-nct07146360-2025-08-28`, retrieved 2026-10-26)
- Primary completion: 2017-11-21 (actual) (ClinicalTrials.gov record NCT07146360, source copy `cardio:ctgov-nct07146360-2025-08-28`, retrieved 2026-10-26)
- Completion: 2017-12-11 (actual) (ClinicalTrials.gov record NCT07146360, source copy `cardio:ctgov-nct07146360-2025-08-28`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT07146360, source copy `cardio:ctgov-nct07146360-2025-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07146360-2025-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
- Condition: Myocardial Infarction (MI)
- Intervention (Biological): Revelise (GENERIUM, Russia)
- Intervention (Biological): Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Lead sponsor: AO GENERIUM
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry lists this organization as the lead sponsor: AO GENERIUM (`cardio:org-ao-generium`)

## Provenance

Content hash: e03126f55a4a3a82af5f60cb1214a71aae27948af903957f34c1700fde1b2ca9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
